Cavitation Board Recommends BrightFlixx Tender at Estimated $0.0975-$0.1029 Per Share
CVAT sits 48% above its 52-week low of $0.022 on light trading volume (0.3× avg).
Summary
Cavitation's board unanimously recommends shareholders tender into BrightFlixx's all-cash offer, estimated at $0.0975-$0.1029 per share against a $0.0303 last trade, with the final price set at the December 24, 2026 Record Date and the deal cross-conditioned on the Alchemy offer.
Key Events · M&A and Partnerships · CVAT
-
Board Recommends Tendering Into BrightFlixx Offer
At an October 26, 2026 meeting, the board unanimously determined that the BF-CVAT Agreement and the BrightFlixx cash tender are fair and in shareholders' best interests, and recommends that holders accept the offer and tender.
-
Estimated Price of $0.0975-$0.1029 Per Share
The price is $35,000,000 less Company liabilities divided by shares outstanding at the Record Date. Three scenarios produce $0.1029 (no new shares, $738,000 liabilities), $0.0989 (12,519,400 shares issued, $838,000 liabilities) and $0.0975 (plus 5,000,000 placement shares).
-
Every New Share Before December 24 Cuts the Payout
The company may issue up to 5,000,000 shares in private placements before expiration, and 11,269,400 warrant shares plus 1,250,000 note shares are likely in the money versus the offer price, each adding to the denominator.
-
Cross-Conditioned on Alchemy Offer and Fairness Opinion
Each offer is conditioned on consummation of the other. If Alchemy's fairness opinion values it above $7 million, a 5-day renegotiation follows and either party may terminate, which would withdraw both offers.
Analysis · CVAT · Industrial Applications And Services
The board's unanimous recommendation to tender into the BrightFlixx cash offer is the company's formal answer to the bid, and it puts a number on the deal for the first time: roughly $0.0975 to $0.1029 per share, against a last trade of $0.0303 on November 2, 2026. For a company with $94,000 of cash, zero revenue last quarter and a going-concern warning, that is the entire investment case: a cash exit at several times the market price, or continued standalone operations that the board itself says will run out of money within a few quarters. The catch is that the price is not final. It is $35 million less liabilities, divided by shares outstanding at the December 24, 2026 Record Date, so every new share issued before then lowers the per-share payout, including up to 5,000,000 the company is permitted to place, plus warrant and note conversions. The deal is also cross-conditioned on the separate Alchemy offer, and an Alchemy fairness opinion valuing that business above $7 million opens a five-day renegotiation that could terminate both offers. CFIUS clearance is a further condition.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 50.3% of the 199 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVAT was trading at $0.03 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $0.02 to $0.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.